Drug Trial Radar · NCT04556838
Study of VVN001 Ophthalmic Solution in Dry Eye Disease
Last checked: Nov 19, 2026Latest source record: Dec 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
169
Actual
Start
Dec 3, 2020
Primary completion
Dec 1, 2021
Study completion Dec 1, 2021
Sponsor
- Lead sponsor
- VivaVision Biotech, IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2a, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and tolerability and to explore the efficacy activity of VVN001 ophthalmic solution versus vehicle in subjects with dry eye disease.
Conditions
- Dry Eye
Interventions
VVN001 Ophthalmic Solution 1%Drug
VVN001 Ophthalmic Solution 1%
VVN001 Ophthalmic Solution 5%Drug
VVN001 Ophthalmic Solution 5%
VehicleDrug
VVN001 Ophthalmic Solution Vehicle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Inferior Corneal Fluorescein StainingTime frame: Day 84
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lexitas
Durham, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.